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Protein complexes are essential components in many cellular processes. In this
study, a procedure to determine the protein-complex structure from a partial
molecular-replacement (MR) solution is demonstrated using a direct-method-
aided dual-space iterative phasing and model-building program suite, IPCAS
(Iterative Protein Crystal structure Automatic Solution). The IPCAS iteration
procedure involves (i) real-space model building and refinement, (ii) direct-
method-aided reciprocal-space phase refinement and (iii) phase improvement
through density modification. The procedure has been tested with four protein
complexes, including two previously unknown structures. It was possible to use
IPCAS to build the whole complex structure from one or less than one subunit
once the molecular-replacement method was able to give a partial solution. In
the most challenging case, IPCAS was able to extend to the full length starting
from less than 30% of the complex structure, while conventional model-building
procedures were unsuccessful.
1. Introduction
Protein complexes have been found to be essential compo-
nents of almost every cellular process (Hartwell et al., 1999;
Phizicky & Fields, 1995). Individual proteins can connect in
the protein-interaction network through complexity and
modularity and work together to accomplish a common
function (Newman, 2006; Pereira-Leal et al., 2006; Baraba´si &
Oltvai, 2004). Proteins with more than one polypeptide or
subunit are also found in many different protein families.
Many protein complexes have been well characterized, among
which the classical examples include haemoglobin (Hardison,
1996), tryptophan synthetase (Raboni et al., 2009) and RNA
polymerase (Hurwitz, 2005). Other well known multi-subunit
proteins include metabolic enzymes, the DNA-replication
complex, the nuclear pore complex, ribonucleoproteins etc.,
which are usually called protein machines (Alberts & Miake-
Lye, 1992). Another different kind of protein complex is a
transient protein complex that controls numerous cellular
processes, such as protein modification (phosphorylation,
glycosylation and acylation etc.), transcription-complex
recruitment and assembly, the transportation of proteins
across membranes, chaperonin-aided native protein folding,
translation-cycle regulation and cellular communication
(Phizicky & Fields, 1995).
X-ray crystallographic structures of protein complexes can
reveal high-resolution details of the structural interactions,
give clues to interaction mechanisms and provide a basis and a
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template for many experimental and computational approa-
ches such as interruption of interaction, binding-affinity
maturation and the computational prediction or design of
protein–protein interactions (Aloy et al., 2005; Kortemme &
Baker, 2004).
Identifying the structure of one of the subunits is a good
starting point to study the whole complex. Here, we report a
demonstration of IPCAS (Iterative Protein Crystal structure
Automatic Solution), which derives the complete complex
structure from a partial molecular-replacement (MR) solution.
The IPCAS pipeline is a direct-method-aided dual-space
iterative phasing and model-building procedure which consists
of SAD/SIR direct phasing and fragment extension (Hao et al.,
2000; Wang et al., 2004) and partial-model extension without
SAD/SIR information (He et al., 2007). The graphical user
interface (GUI) was published in 2010 (Zhang et al., 2010).
This study only utilizes the feature of partial model extension
without SAD/SIR information. The iteration procedure
involves (i) real-space model building and refinement by
ARP/wARP (Langer et al., 2008), Buccaneer (Cowtan, 2006),
phenix.autobuild (Terwilliger et al., 2008), RESOLVE
(Terwilliger, 2003) and REFMAC5 (Murshudov et al., 2011),
(ii) direct-method-aided reciprocal-space phase refinement
by OASIS (Zhang et al., 2010) and (iii) phase improvement
through density modification by DM (Winn et al., 2011) or
RESOLVE (Terwilliger, 2000). To apply a direct method in
reciprocal-space phase refinement based on the built model,
the conventional direct-method probability formula has been
revised (He et al., 2007).
To evaluate the IPCAS pipeline, the following three test
cases were carefully selected from a practical perspective and
one case was randomly selected from the PDB to demonstrate
the capability of IPCAS to deal with low-resolution data.
(i) The Hha–H-NS complex. -Haemolysin expression-
modulating protein (Hha) and histone-like nucleoid struc-
turing protein (H-NS) are both nucleoid-associated proteins
from bacteria. In Escherichia coli, Hha can bind to H-NS and
the formation of the complex is essential for silencing the
expression of the toxin -haemolysin (Ali et al., 2013; Nieto et
al., 2002). In this work, the Hha–H-NS64 complex (1.8 A˚
resolution) represents a difficult case in which the search
model (an H-NS46 dimer; PDB entry 1ov9; Cerdan et al., 2003)
shares 65% sequence identity with the H-NS part of the target
protein and is less than 30% of the overall complex structure
in size (details of data collection and test results are listed in
Tables 1 and 2). This structure was previously unknown and
the full structure with biological functions will be published
elsewhere.
(ii) NDM-1 protein with an MBP tag. Maltose-binding
protein (MBP) is often used in E. coli expression systems to
help in the folding and to increase the solubility of the target
protein and is also used as an affinity tag to help in purification
(Lebendiker & Danieli, 2011). In crystallography, MBP can
also help to phase the MBP-fusion protein by the molecular-
replacement (MR) method. New Delhi metallo--lactamase-1
(NDM-1) is one of the class B -lactamases. The first NDM-1
structure was solved by single-wavelength anomalous disper-
sion (SAD) with data collected at the zinc absorption edge
(Zhang & Hao, 2011). In this complex at 2.2 A˚ resolution,
NDM-1 composes about 36% of the length of the sequence
and MBP makes up 57% of the length of the sequence. Here,
we demonstrated that the NDM-1 structure could be obtained
by IPCAS starting from the MR solution using MBP as a
search model. Similarly, using the NDM-1 structure as an MR
search model, the longer MBP part could also be built by
IPCAS.
(ii) CD38–nanobody complex. Antibody–antigen inter-
action is a central part of the immune system and a typical
form of protein complexes. However, the structural variability
of antibodies leads to difficulties in structural determination
(Davies et al., 1990). Although the use of the MR method to
determine the structures of antibodies or antibody–antigen
complexes has long been known (Bru¨nger, 1993), it is still
not straightforward to determine the structure of novel or
designed antibodies in practice. CD38 is a multi-functional
enzyme involved in many cellular processes (Lee, 2006) and is
a promising therapeutic target for antibody therapy in cancer
treatment (Chillemi et al., 2013; Stevenson, 2006). In this study,
we report the structure of a CD38–nanobody complex (2.3 A˚
resolution) obtained using the CD38 molecule (55% of the
sequence) as an MR search model and the designed nanobody
structure could be built by IPCAS. The biological functions of
this complex will be reported elsewhere.
(iv) PDB entry 4owr, a randomly selected lower resolution
case (Quan et al., 2014). Model building at low resolution is
always a challenge owing to the limited number of observa-
tions compared with the large number of parameters to be
defined (Karmali et al., 2009). The 4owr complex (3.15 A˚) was
randomly selected from the PDB to test how IPCAS was able
to deal with low-resolution data. The 4owr complex consists
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Table 1
Crystallographic data-collection and refinement statistics.
Values in parentheses are for the highest resolution shell.
Hha–H-NS NDM-1–MBP CD38–nanobody
Wavelength (A˚) 0.9793 0.9792 0.9793
Resolution range (A˚) 50–1.8
(1.86–1.80)
50–2.2
(2.28–2.20)
50–2.3
(2.38–2.30)
Space group P1 C121 P212121
Unit-cell parameters
a (A˚) 41.4 207.3 88.6
b (A˚) 45.3 74.0 96.2
c (A˚) 47.5 53.3 133.8
 () 68.4 90 90
 () 88.1 104.2 90
 () 85.8 90 90
Total reflections 195794 417531 2876430
Unique reflections 28838 (2852) 72688 (6963) 51358 (5075)
Completeness (%) 97.55 (96.0) 98.8 (97.1) 99.7 (100.0)
Mean I/(I) 41.31 (3.38) 15.57 (2.33) 21.81 (3.39)
Wilson B factor (A˚2) 39.9 41.6 41.5
Rsym or Rmerge 0.033 (0.309) 0.070 (0.465) 0.092 (0.576)
Rwork 0.1800 0.1883 0.2075
Rfree 0.2197 0.2349 0.2361
No. of non-H atoms 2621 4805 6094
Protein residues 261 598 727
R.m.s.d., bonds (A˚) 0.011 0.009 0.011
R.m.s.d., angles () 1.38 1.15 1.35
of three chains: chain A (57%), chain B (10%) and chain C
(32%), in which chain A was taken as the starting model for
IPCASmodel completion after Phaser had placed it within the
unit cell. Finally, we demonstrated that model completion at
low resolution can also be successful.
2. Method
Before the structure-completion procedure, a molecular-
replacement (MR) solution from a partial model should be
identified. If the MR solution is not of sufficient quality to
allow subsequent model building, manual improvement of the
solution structure might be necessary, such as manual refine-
ment based on the fit between the model structure and the
electron-density map using Coot (Emsley et al., 2010; a
detailed procedure with an example will be described in x3.1).
The MR solution structure and the initial map from this
structure are then taken as a starting point for IPCAS to
perform model completion by iteration, including real-space
refinement, direct-method-aided reciprocal-space refinement
and model building, with sequence and solvent content
assigned. The entire workflow is shown in Fig. 1. The indivi-
dual program parameters that IPCAS calls can be adjusted in
a graphical user interface (GUI); however, in this study the
default values of these parameters are used in all four cases.
IPCAS usually runs ten iterations of real-space refinement,
direct-method-aided reciprocal-space refinement and model
building, and the user can then decide whether or not more
iterations are required depending
on whether the results are
converging.
3. Test results
Four protein complexes were
tested with IPCAS: the Hha–
H-NS complex, the NDM-1–MBP
complex, the CD38–nanobody
complex and PDB entry 4owr.
The data-collection and refine-
ment statistics for the first three
cases are listed in Table 1. Phaser
(McCoy et al., 2007) was first
applied to obtain a partial MR
solution. The iteration control in
IPCAS was set as ‘OASIS–DM–
Buccaneer’ for all four cases. As a
comparison, the same (or a
greater) number of iterations of
Buccaneer alone were carried out.
The details of the four test cases
and the test results are listed in
Table 2.
3.1. Model completion of the
Hha–H-NS complex
There are four chains in an
Hha–H-NS complex, with one
H-NS dimer in the core region
and two Hha molecules binding
at each side of the H-NS dimer. In
our tests, an H-NS46 dimer (PDB
entry 1ov9; 65% sequence iden-
tity) was taken as a search model
for MR. From the Phaser result
listed in Table 2, the MR solution
was not quite straightforward,
with an LLG value of less than
100. Thus, the first IPCAS trial
directly using the MR solution as
research papers
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Figure 1
Workflow of IPCAS model completion from a partial molecular-replacement solution.
Table 2
Model-completion test results.
Case Hha–H-NS NDM-1–MBP CD38–nanobody 4owr
Residues in asymmetric unit 302 642 828 586
MR model (PDB entry) H-NS dimer
(1ov9)
MBP monomer
(1y4c)
NDM-1 monomer
(3q6x)
CD38 monomer
(3ops)
Chain A
(4owr)
Sequence identity between
starting and search models
(%)
65 100 100 100 100
No. of residues in the starting
model (% of the complex)
89 (29.5%) 367 (57.2%) 229 (35.7%) 456 (55.0%) 335 (57.0%)
Phaser (CCP4)
RFZ 9.3 8.1 24.2 6.8 3.9
TFZ † 16.1 16.0 26.6 12.6
LLG 74 2383 1305 1847 2093
Starting FOM 0.456 0.522 0.426 0.508 0.651
IPCAS
No. of residues built 269 (89%) 603 (94%) 602 (94%) 747 (90%) 566 (97%)
R factor/Rfree (%) 24.6/28.9 22.7/27.9 23.5/27.9 24.2/28.2 25.7/32.2
No. of C < 1 A˚‡ 250 586 588 712 429
Buccaneer (CCP4)
No. of residues built 188 (62%) 606 (94%) 628 (98%) 773 (93%) 394 (67%)
R factor/Rfree (%) 44.3/51.8 25.8/31.6 24.7/29.7 26.8/31.0 35.9/45.5
No. of C < 1 A˚‡ 76 564 583 707 348
† The TFZ score is not applicable in space group P1. ‡ C is the positional deviation of C atoms in the built model from
those of the final structure.
a starting structure for model completion could not proceed at
the density-modification step as DM stopped automatically
because the figure-of-merit (FOM) criterion was not met.
Therefore, the MR solution from Phaser was manually
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Figure 2
IPCAS model-completion results for four cases. The left five figures are model-completion status (percentage built/sequenced/R factor/Rfree) per cycle
for the Hha–H-NS complex (a), the NDM-1–MBP complex, starting from MBP (d) and starting from NDM-1 (g), the CD38–nanobody complex (j) and
the 4owr complex (m). The middle five figures (b, e, h, k, n) are the initial models for each case (cyan). The right five figures (c, f, i, l, o) are the IPCAS
model-completion results (yellow) for the five structures.
adjusted via Coot and REFMAC5. The model sequence was
replaced by the target sequence and several terminal residues
were removed as they did not fit well into the density. After
several rounds of manual refinement, the R and Rfree values
decreased from 53.36 and 54.49% (the MR solution) to 46.18
and 50.63%, respectively, and the FOM increased from 0.313
to 0.456. The refined model was then delivered to IPCAS for
extension. After 20 cycles of iteration, 269 residues (about
89% of the full sequence) were correctly modelled starting
from the 89 residues of the MR solution. The model-
completion rate became convergent after about the 15th cycle
(Fig. 2a). The initial structure is shown in Fig. 2(b) and the final
structure after cycle 20 is shown in Fig. 2(c). The widely used
autobuilding program Buccaneer (v.1.5.2 in CCP4 v.6.3.0)
alone did not give a correct result using either the Phaser
solution or the manually refined initial structure.
We also attempted to use DEN refinement (Schro¨der et al.,
2010) and model morphing (Terwilliger et al., 2012) with
default parameters to improve the initial MR model quality.
The R and Rfree values decreased from 53.36 and 54.49% to
48.45 and 50.34%, respectively, in DEN refinement, and to
49.13 and 53.30,% respectively, in model morphing. However,
neither Buccaneer nor IPCAS could extend the refined model
any further. The r.m.s.d. of C atoms between the DEN-
refined model and the manually refined model was 3.74 A˚
(part of the secondary structure collapsed after DEN refine-
ment in this case) and the r.m.s.d. between the morphed model
and the manually refined model was 1.08 A˚. The r.m.s.d.s of C
atoms between the final refined structure and the manually
refined model, the DEN-refined model and the morphed
model were also calculated, and the values were 0.63, 3.85 and
1.29 A˚, respectively.
3.2. Model completion of the NDM-1–MBP complex
The NDM-1–MBP complex has two chains in the structure:
one molecule of NDM-1 and one molecule of MBP. NDM-1 is
about half the length of MBP. To obtain the NDM-1 structure,
MBP (PDB entry 1y4c; LaPorte et al., 2004) was taken as an
MR search model and the solution given by Phaser was of
sufficient quality to allow IPCAS to build about 94% of the
sequence. As shown in Fig. 2(d), the model-completion rate
became convergent after about the third cycle. The initial
structure of MBP is shown in Fig. 2(e) and the final structure
after cycle 10 is shown in Fig. 2( f). To further test the model-
completion capability of IPCAS, the NDM-1 molecule was
used as the MR search model. The result was similar apart
from that building from the smaller subunit requires more
cycles of iteration: the model-completion rate became
convergent after about the seventh cycle (Fig. 2g). The initial
structure of NDM-1 is shown in Fig. 2(h) and the final struc-
ture after cycle 10 is shown in Fig. 2(i). In comparison,
Buccaneer alone could complete model building within ten
cycles starting from MBP and within 20 cycles starting from
NDM-1.
3.3. Model completion of the CD38–nanobody complex
The CD38–nanobody complex has four chains per asym-
metric unit with two molecules of CD38 and two molecules of
nanobody. In the test, a CD38 monomer was sent to Phaser to
search for two copies and the solution was quite clear. Starting
from the Phaser solution, IPCAS could build about 90% of the
complex sequence and the model-completion rate became
convergent after about the third cycle (Fig. 2j). The initial
structure is shown in Fig. 2(k) and the final structure after ten
cycles is shown in Fig. 2(l). In comparison, Buccaneer alone
could finish model building within 15 cycles. The r.m.s.d. of the
C atoms between nanobody-bound CD38 and apo CD38
(PDB entry 1yh3; Liu et al., 2005) is 1.26 A˚, suggesting a small
conformational change upon ligand binding.
3.4. Model completion of the 4owr complex
The complex with PDB code 4owr is composed of three
chains in an asymmetric unit with space group P4212. In the
test, chain A (57%) was sent to Phaser to search for one copy
and the solution was quite clear. The MR solution was then
sent to IPCAS, and after ten cycles of iteration about 97% of
the sequence including the main parts of all three chains could
be built (Fig. 2m). The initial structure is shown in Fig. 2(n)
and the final structure after ten cycles is shown in Fig. 2(o). In
comparison, Buccaneer alone did not extend the initial model
further.
3.5. Summary
In our tests, IPCAS was able to extend the starting struc-
tures from as low as 30% of the complex to almost complete
for all three cases, with reasonable R and Rfree values. For the
Hha–H-NS complex IPCAS initially failed to extend the
structure directly from the Phaser solution, but after the FOM
value of the starting model was increased from 0.313 to 0.456
by manual refinement IPCAS could eventually extend the
complex structure from less than 30% to almost 90%. In
contrast, the widely used autobuilding program Buccaneer
(from the CCP4 suite) could successfully handle only the two
cases with promising MR solutions (high starting fraction and
high LLG) and not the toughest case of the Hha–H-NS
complex nor the lower resolution case PDB entry 4owr.
4. Discussion
Structural studies of protein complexes are an important
approach in understanding related cellular processes. In this
study, we report a procedure that is particularly suitable for
solving crystallographic protein-complex structures based on
direct-method-aided dual-space iterative phasing and model
building implemented in IPCAS. Our procedure shows an
advantage, particularly for a test case in which only a small
fraction/subunit (less than 30% of the complex) has a known
homologue structure, compared with the widely used model-
building approach Buccaneer. With an MR solution of suffi-
cient quality, the IPCAS workflow can be quite automatic. In
the challenging case where the MR solution does not have
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sufficiently high quality, the starting model should be
improved (until the FOM is larger than about 0.4 in our test)
before being delivered to IPCAS. Also, our tests show that
IPCAS is capable of low-resolution phasing (lower than 3 A˚)
with a sufficient known fraction (greater than 50%) of the
complex in the starting model. We hope that our procedure
may provide an option for solving protein-complex structures,
especially for difficult cases.
5. Program availability
The program IPCAS can be downloaded at the website http://
cryst.iphy.ac.cn.
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